Patents by Inventor Amanda Przedpelski

Amanda Przedpelski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified Clostridial Neurotoxins as Vaccine and Conjugate Vaccine Platforms
    Publication number: 20240139332
    Abstract: Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.
    Type: Application
    Filed: October 3, 2022
    Publication date: May 2, 2024
    Inventors: Joseph T. Barbieri, Eric A. Johnson, Sabine Pellett, William H. Tepp, Amanda Przedpelski
  • Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms
    Patent number: 11491239
    Abstract: Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: November 8, 2022
    Assignees: The Medical College of Wisconsin, Inc., Wisconsin Alumni Research Foundation
    Inventors: Joseph T. Barbieri, Eric A. Johnson, Sabine Pellett, William H. Tepp, Amanda Przedpelski
  • COVID-19 VACCINE
    Publication number: 20210300970
    Abstract: Provided herein are antigenic peptides comprising the SARS-CoV-2 spike protein receptor binding domain (CRBD) polypeptide or portions thereof, linked to a non-catalytic, non-toxic tetanus toxin variant (i.e., a modified tetanus toxin or “MTT”) and vaccine compositions comprising the same. In addition, provided herein are methods for making and using CRBD-MTT fusion proteins as immunogenic agents.
    Type: Application
    Filed: March 24, 2021
    Publication date: September 30, 2021
    Inventors: Joseph T. Barbieri, Amanda Przedpelski, Eric A. Johnson, Sabine Pellett, William H. Tepp
  • MODIFIED CLOSTRIDIAL NEUROTOXINS AS VACCINES AND CONJUGATE VACCINE PLATFORMS
    Publication number: 20200384120
    Abstract: Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.
    Type: Application
    Filed: December 17, 2018
    Publication date: December 10, 2020
    Applicants: THE MEDICAL COLLEGE OF WISCONSIN, INC., WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Joseph T. Barbieri, Eric A. Johnson, Sabine Pellett, William H. Tepp, Amanda Przedpelski
  • UNIVERSAL PLATFORM FOR TARGETING THERAPIES TO TREAT NEUROLOGICAL DISEASES
    Publication number: 20190321453
    Abstract: The present invention provides a universal delivery platform of functional, heterologous compounds to specific cells using toxins modified to include a heterologous compound. In one embodiment, the toxin is an AB5 toxin. In one embodiment, the AB5 toxin is a heat-labile enterotoxin from E. coli (LT), including LTI, LTII, LTIIa, LTIIb, LTIIc and other recombinant forms of LT. Methods of use are also provided.
    Type: Application
    Filed: April 25, 2019
    Publication date: October 24, 2019
    Inventors: Joseph T. Barbieri, Chen Chen, Amanda Przedpelski, Eric A. Johnson, Sabine Pellett
  • UNIVERSAL PLATFORM FOR TARGETING THERAPIES TO TREAT NEUROLOGICAL DISEASES
    Publication number: 20170281737
    Abstract: The present invention provides a universal delivery platform of functional, heterologous compounds to specific cells using toxins modified to include a heterologous compound. In one embodiment, the toxin is an AB5 toxin. In one embodiment, the AB5 toxin is a heat-labile enterotoxin from E. coli (LT), including LTI, LTII, LTIIa, LTIIb, LTIIc and other recombinant forms of LT. Methods of use are also provided.
    Type: Application
    Filed: September 29, 2015
    Publication date: October 5, 2017
    Inventors: Joseph T. Barbieri, Chen Chen, Amanda Przedpelski, Eric A. Johnson, Sabine Pellett